Can acidosis and hyperphosphataemia result in increased erythropoietin dosing in haemodialysis patients?
Acidosis and hyperphosphataemia are associated with apparent increased erythropoietin dosing requirements. While this study did not evaluate the mechanism of such requirements and indeed many mechanisms might be possible, a rightward shift in the oxygen-haemoglobin dissociation curve resulting in down-regulation of erythropoietin receptors is considered consistent with the data and present knowledge.
This study showed that the efficacy of SCS in reduction of pain intensity, GPE, and QOL in a well-defined chronic CRPS-I population was not predicted by pain catastrophizing. Therefore, we conclude that a high level of pain catastrophizing in patients with CRPS-I is not a contraindication for SCS treatment.